Search Results 441-450 of 14090 for SC

  1. A Phase 2 Master Protocol Assessing Inebilizumab And Blinatumomab In Autoimmune Diseases - Mayo Clinic

    ... (SC) blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part A) and in adult participants with ...

  2. Publications - Hector R. Cajigas, M.D. - Mayo Clinic

    Khan SL, Paoli CJ, Kime N, Williams K, Rendon GG, Tonelli AR, Cajigas H, Mathai SC, Sahay S. Treatment Patterns in Patients With Incident Pulmonary ...

  3. Knee Arthritis Clinical Trials - Mayo Clinic Research

    The purpose of this study is to determine the safety of sc-rAAV2.5IL-1Ra, a gene therapy carried by a virus and delivered by injection into the knee joint of ...

  4. A Study Evaluating The Safety, Efficacy, And Pharmacokinetics Of Mosunetuzumab Monotherapy In Participants With Select B-Cell Malignancies (MorningSun) - Mayo Clinic

    The purpose of this study is to evaluate the effectiveness, safety, and pharmacokinetics of mosunetuzumab subcutaneous (SC) formulation in participants with ...

  5. Vedolizumab Subcutaneous Long-Term Open-Label Extension Study - Mayo Clinic

    The purpose of this study is to obtain long term safety and tolerability data of vedolizumab subcutaneous (vedolizumab SC) in participants with ulcerative ...

  6. Publications - John R. Giudicessi, M.D., Ph.D. - Mayo Clinic

    ... SC, Wada Y, Wanguemert F, Zorio E, Ackerman MJ, Leenhardt A, Sanatani S, Tanck MW, Wilde AA. Catecholaminergic polymorphic ventricular tachycardia mediated ...

  7. Faculty - Department of Molecular Pharmacology and Experimental Therapeutics Research - Mayo Clinic Research

    Camilleri, Michael M.D., D.Sc. camilleri.michael@mayo.edu; Professor of Medicine; Professor of Pharmacology; Professor of Physiology; Publications · Chini ...

  8. Collaborators - Cellular and Molecular Physiology of Gastrointestinal Disorders Laboratory - Mayo Clinic Research

    Georgine Faulkner, Ph.D. International Centre for Genetic Engineering and Biotechnology Trieste, Italy; Braden Kuo, M.D., M.Sc. Massachusetts General Hospital

  9. Judy C. Boughey, M.D. - Doctors and Medical Staff - Mayo Clinic

    ... South Carolina Chapter of the ACS, Charleston, SC. 2000. First Place Award, Resident Paper CompetitionSC-ACS Committee on Trauma, Greenville, SC. 1995. Henry ...

  10. A Study To Assess Adverse Events And Change In Disease Activity Of Risankizumab Subcutaneous Induction Treatment For Moderately To Severely Active Crohn's Disease - Mayo Clinic

    The purpose of this study is to assess how safe and effective risankizumab subcutaneous (SC) induction treatment is in treating moderately to severely ...